New Insights into the Role of Sex Steroid Hormones in Pregnancy: Possible Therapeutic Approach by Sex Steroid Hormones for the Treatment of Both Preeclampsia and Preterm Labor

S. Mizutani; E. Mizutani

doi:10.1055/s-0034-1398622

Experimental and Clinical Endocrinology & Diabetes, Inhaltsverzeichnis

Exp Clin Endocrinol Diabetes 2015; 123(03): 159-164
DOI: 10.1055/s-0034-1398622

Review

New Insights into the Role of Sex Steroid Hormones in Pregnancy: Possible Therapeutic Approach by Sex Steroid Hormones for the Treatment of Both Preeclampsia and Preterm Labor

Authors

S. Mizutani

¹Daiya Building Ladys’ Clinic, Meieki, Nakamura-ku, Nagoya, Japan
E. Mizutani

¹Daiya Building Ladys’ Clinic, Meieki, Nakamura-ku, Nagoya, Japan

Abstract

Fetal peptide hormones are essential for the development of fetus, which increase in accordance with pregnancy term. Concentration of these hormones within the feto-placental unit is normally higher than that of maternal circulation. Since these hormones are biologically active, the leakage of these hormones into the maternal circulation is regulated by degradation activity by placental aminopeptidases, in order to maintain the balance between carriage of pregnancy and onset of labor.

Because the concentration of these hormones, being regulated by the amount of endogenous production and by physiological degradation by enzymes in the blood and tissue, the balance between production and degradation is a definitive element for maintaining normal gestation and term delivery.

The changes of the balance between fetal angiotensin II (A-II) and vasopressin (AVP) and

A-II and AVP degrading enzymes, between aminopeptidase A (APA) and placental leucine aminopeptidase( P-LAP) – in the placenta and maternal blood due to fetal stress such as hypoxia – are the provable causes of preeclampsia or preterm labor.

Induction of APA and P-LAP by estradiol benzoate (E2) and progesterone (P) from placenta has been demonstrated. They are involved in the regulation of fetal peptide hormones via placental aminopeptidases in homeostasis of pregnancy.

Recently it was shown that both APA and P-LAP could be potentially safe and effective drugs for preeclampsia and preterm labor. The authors’ proposed sex steroid treatment with dose increasing manner by gestational week (sex steroid treatment) for severe preeclampsia and preterm labor could be candidates replacing conventional treatments. In light of lacking safe and effective medication, the proposed sex steroid treatment is worthwhile for the prospective controlled studies for the treatment of both preeclampsia and preterm labor.

Key words

preeclampsia - preterm labor - sex steroid treatment - new role of sex steroid hormones in pregnancy

Volltext

Referenzen

References
1 Broughton Pipkin F, Symonds EM. Factors affecting angiotensin II concentrations in the human infant at birth. Clin Sci Mol Med 1977; 52: 449-456
2 Oosterbaan HP, Swaab DF. Amniotic oxytocin and vasopressin in relation to human development and labour. Early Hum Develop 1989; 19: 253-262
3 Iwasaki Y, Kinoshita M, Ikeda K et al. Trophic effect of angiotensin II, vasopressin and other peptides on the cultured ventral spinal cord of rat embryo. J Neuro Sci 1991; 103: 151-155
4 Ervin MG, Kullama LK, Ross MG et al. Vasopressin receptors and effects during fetal development. Reg Peptide 1993; 45: 203-208
5 Sakura H, Lin TY, Doi M et al. Purification and properties of oxytocinase, a metalloenzyme. Biochem Int 1981; 2: 173-179
6 Mizutani S, Sumi S, Oka R et al. In vitro degradation of oxytocin by human placental subcellular fractions, pregnancy sera and purified placental aminopeptidases. Exp Clin Endocrinol 1985; 86: 310-316
7 Mizutani S, Okano K, Hasegawa E et al. Aminopeptidase A in human placenta. Biochim Biophs Acta 1981; 662: 168-170
8 Mizutani S, Akiyama H, Kurauchi O et al. In vitro degradation of angiotensin II (A-II) by human placental subcellular fractions, pregnancy sera and purified placental aminopeptidases. Acta Endocrinol 1985; 110: 135-139
9 Mizutani S, Naruse K, Hattori A et al. Physiological and pathophysiological roles of placental aminopeptidase in maternal sera: possible relation to preeclampsia and preterm delivery. Expert Opin Med Diagn 2009; 3: 479-491
10 Phat VN, Camilleri JP, Bariety J et al Immunohistochemical characterizationof renin-containing cells in the human juxtaglomerular apparatus during embryonal and fetal development. Lab Invest 1981; 45: 387-390
11 Cheung CY. Fetal endocrinology. In Reece EA, Hobbins JC, Hahoney MJ, Petrie RH. (eds.). Medicine of the fetus and mother. Philadelphia: JB Lippincott; 1992. P. 155-172
12 Kingdam JC, McQueeen J, Connell JM et al. Fetal angiotensin II levels and vascular (type I) angiotensin receptors in pregnancies complicated by intrauterine growth retardation. Br J Obstet Gynecol 1993; 100: 476-482
13 DeVane GW, Porter JC. An apparent stress-induced release of arginine vasopressin by human neonates. J Clin Endocrinol Metab 1980; 51: 1412-1416
14 Mizutani S, Akiyama H, Kurauchi O et al. Plasma angiotensin I and serum placental leucine aminopeptidase(P-LAP)in pre-eclampsia. Arch Gynecol 1985; 236: 165-172
15 Mizutani S, Yamada R, Kurauchi O et al. Serum aminopeptidases A(APA) in normal pregnancy and pregnancy complicated by preeclampsia. Arch Gynecol. 1987. 240. 27-31
16 Safwat AM, Mizutani S, Salem HT et al. Changes of placental proteases, which degrade vasoactive peptides, in maternal sera at the onset of preeclampsia. Med Sci Res 1995; 23: 123-126
17 Kozaki H, Itakura A, Okamura M et al. Maternal serum placental leucine aminopeptidase(P-LAP)/oxytocinase and preterm delivery. Int J Gynecol Obstet 2001; 73: 207-213
18 Chard T, Hudson CN, Edwards CR et al. Release of oxytocin and vasopressin by the human foetus during labour. Nature 1971; 234: 352-354
19 Roberts RM, Bazer FW, Baldwin N et al. Progesterone induction of lysozyme and peptidase activities in the porcine uterus. Arch Biochem Biophys 1976; 177: 499-507
20 Kurauchi O, Mizutani S, Nomura S et al. Effects of progesterone and estradiol on aminopeptidases A(AAP) and leucine aminopeptidases (LAP) activities in the pregnancy serum and placenta of the rat. Exp Clin Endocrinol 1989; 93: 90-94
21 Miura S, Morita A, Erickson RH et al. Content and turnover of rat intestinal microvillus aminopeptidase-effect of methylpredonisolone. Gastroenterology 1983; 85: 1340-1349
22 Friedland J, Setton C, Siverstein E. Angiotensin converting enzyme: induction by steroids in rabbit alveolar macrophages in culture. Science 1977; 197: 64-65
23 Davis MH. Hormonal regulationof dipeptidyl-aminopeptidase I activity in cultured human fibroblasts. Arch Biochem Biophs 1987; 254: 498-503
24 Yasuda Y, Mizutani S, Kurauchi O et al. Induction by cortisol of aminopeptidases in tissue culture. Horm metab Res 1992; 24: 110-114
25 Diamant YZ, Neuman S, Shafrir E. Effects of chorionic gonadotropin, triamcinolone, progesterone and estrogen on enzymes of placenta and liver in rats. Biochem Biophys Acta 1975; 385: 257-267
26 Ino K, Goto S, Okamoto T et al. Expression of aminopeptidase N on human choriocarcinoma cells and cell growth suppression by inhibition of aminopeptidase N activity. Jpn J Cancer Res 1994; 85: 927-933
27 Ringler GE, Strauss III JF. In vitro systems for the study of human placental endocrine function. Endocr Rev 1990; 11: 105-123
28 Katsumata Y, Nomura S, Ino K et al. Progesterone stimulates the expression of aminopeptidase A/angiotensinase in human choriocarcinoma cells. Placenta 2001; 22: 831-836
29 Rogi T, Tsujimoto M, Nakazato H et al. Human placental leucine aminopeptidase/oxytocinase. a new member of type II membrane-spanning zinc mettalopeptidase family. J Biol Chem 1996; 271: 257-261
30 Gergopoulos K, Moore DD, Derfer B. Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment. Science 1992; 258: 808-812
31 Ito T, Nomura S, Okada M et al. Transcriptional regulation of human placental leucine aminopeptidase/oxytocinase gene. Mol Hum Reprod 2001; 7: 887-894
32 Ito T, Nomura S, Okada M et al. AP2 and Ikaros regulate transcription of human placental leucine aminopeptidase/oxytocinase gene. Biochem Biophys Res Commun 2002; 290: 1048-1053
33 Iwanaga K, Nomura S, Ito T et al. Placental leucine aminopeptidase/oxytocinase gene regulation by activator protein-2 in BeWo cell model of human trophoblast differentiation. FEBS Lett 2003; 552: 120-124
34 Alexander DP, Forsling MI, Martin MI et al. The effect of maternal hypoxia on fetal pituitary hormone release in the sheep. Biol Neonate 1972; 21: 219-228
35 Bimbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000; 11: 406-410
36 Hariyama Y, Itakura A, Okamura M et al. Placental aminopeptidase A as a possible barrier of angiotensin II between mother and fetus. Placenta 2000; 21: 621-627
37 Horio J, Nomura S, Okada M et al. Structural organization of the 5′-end and chromosomal assignment of human placental leucine aminopeptidase/oxytocinase gene. Biochem Biophys Res Commun 1999; 262: 269-274
38 Johnson MP, Fitzpatrick E, Dyer TD et al. Identification of two novel quantitative trait loci for pre-eclampsia susceptibility on chromosomes 5q and 13q using a variance components-based linkage approach. Mol Hum Reprod 2007; 13: 61-67
39 Hattori A, Matsumoto H, Mizutani S et al. Molecular cloning of adipocyte-derived leucine aminopeptidase highly related to placental leucine aminopeptidase/oxytocinase. J Biochem 1999; 125: 931-938
40 Iwase A, Nomura S, Mizutani S. Characterization of a secretase activity for placental leucine aminopeptidase. Arch Biochem Biophys 2001; 393: 163-169
41 Ito N, Nomura S, Iwase A et al. ADAMs, a disintegrin and metalloproteases, mediating shedding of oxytocinase. Biochem Biophys Res Commun 2004; 314: 1008-1013
42 Laigaard J, Sorensen T, Placing S et al. Reduction of the disintegrin and metalloproteases ADAM12 in preeclampsia. Obstet Gynecol 2005; 106: 144-149
43 Gack S, Marme A, Marme F et al. Preeclampsia: increased expression of soluble ADAM12. J Mol Med(Berl) 2005; 83: 887-896
44 Smith GV, Smith OW. Estrogen and progestin metabolism in pregnancy. J Clin Endocrinol 1941; 1: 477-484
45 Hoover RN, Hyer M, Pfeiffer RM et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med 2011; 365: 1304-1314
46 Mizutani S, Noto H, Inamoto Y et al. Estimation of placental leucine aminopeptidase in abnormal pregnancy sera. Acta Obst Gynec Jpn 1979; 31: 493-498
47 Mizutani S, Kurauchi O, Ito Y et al. Positive effect of estradiol and progesterone in severe preeclampsia. Exp Clin Endocrinol 1988; 92: 161-170
48 Sammour MB, El-makhzangy MN, Fawzy MM et al. Progesterone therapy in pregnancy induced hypertension: therapeutic value and hormonal profile. Clin Exp Hypertens B 1982; 1: 455-478
49 Sammour MB, El-Kabarity H, Fawzy MM et al. Prevention and treatment of pregnancy-induced hypertension(preeclampsia) with progestogens. J Steroid Biochem Mol Biol 2005; 97: 439-440
50 Ryan KJ. Placental synthesis of steroid hormones. In: Tulchinsky D, Ryan KJ. (eds.). Maternal-fetal endocrinology. Philadelphia: W.B. Saunders; 1980: 3-16
51 Naruki M, Mizutani S, Yamada R et al. Changes in maternal serum oxytocinase activities in preterm labor. Med Sci Res 1995; 23: 797-802
52 Meis PJ, Klebanoff M, Thom E et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone capronate. N Engl J Med 2003; 348: 2379-2385
53 Likis FE, Valez Edwards DR, Andrews JC et al. Progestogens for preterm birth prevention. Obst Gynec 2012; 120: 897-907
54 Rozenberg P, Chauveaud A, Derulle P et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone capronate: A randomized controlled trial. Am J Ob Gynec 2012; 206: 206.e1-206.e9
55 Mendelson CR. Minireview: fetal-maternal hormonal signaling in pregnancy and labor. Mol Endocrinol 2009; 23: 947-954
56 Babischkin JS, Grimes RW, Pepe GJ et al. Estrogen stimulation of P450 cholesterol side-chain cleavage activity in cultures of human placenta syncytiotrophoblasts. Biol Reprod 1997; 56: 272-278
57 Assali NS, Clark KE, Zugaib M et al. Effects of estrogenic hormones on uteroplacental hemodynamics and progesterone production in the sheep. Int J Fertil 1978; 23: 219-223
58 Resnik R, Killam AP, Battaglia FC et al. The stimulation of uterine blood flow by various estrogens. Endocrinology 1974; 94: 1192-1196
59 Matsuura S, Itakura A, Ohno Y et al. Effects of estradiol on feto-placental growth in rat. Early Hum Develop 2004; 77: 47-56
60 Mizutani S, Tsunemi T, Mizutani E et al. New insights into the role of aminopeptidases in the treatment for both preeclampsia and preterm labor. Expert Opin Investig Drugs 2013; 22: 1425-1436
61 McDonough PG. Progesterone therapy: benefit versus risk. Fertil Steril 1985; 44: 13-16
62 Brown CM, Garovic VD. Mechanism and management of hypertension in pregnant women. Curr Hypertens Res 2011; 13: 338-346
63 Brown CM, Garovic VD. Drug treatment of hypertension in pregnancy. Drugs 2014; 74: 283-296